Skip to main content
Figure 2 | BMC Neurology

Figure 2

From: Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Figure 2

PML risk stratification in natalizumab-treated MS patients[37]. Based on natalizumab exposure and 285 confirmed PML cases as of 5 September 2012. Prior immunosuppression (IS) data in overall natalizumab-treated patients based on proportion of patients with IS use prior to natalizumab therapy in TYGRIS as of May 2011; and prior IS data in PML patients as of 5 September 2012. The analysis assumes that 55% of natalizumab-treated MS patients were anti-JCV antibody positive and that all PML patients test positive for anti-JCV antibodies prior to the onset and diagnosis of PML. The estimate of PML incidence in anti-JCV antibody negative patients is based on the assumption that all patients received at least 1 dose of natalizumab. Assuming that all patients received at least 18 doses of natalizumab, the estimate of PML incidence in anti-JCV antibody negative patients was generally consistent (0.1/1000; 95% CI 0.00–0.62).

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us